In conclusion, our study of clinical HNSCC cohorts showed that dysregulation of the c-MET/STAT3/AKT signaling pathway was linked to the development of HNSCC, as well as its worse prognoses, resistance to treatment, progression of cancer stem cell-like phenotypes, and resistance to certain drugs. The gene discussed is MET; the disease is cancer.